Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;21(2):76-77.
doi: 10.1038/s41575-023-00881-1.

New options for late-line treatment of metastatic colorectal cancer

Sara Lonardi  1 , Filippo Pietrantonio  2
Affiliations

New options for late-line treatment of metastatic colorectal cancer

Sara Lonardi et al. Nat Rev Gastroenterol Hepatol. 2024 Feb.
No abstract available

PubMed Disclaimer

References

    1. Cervantes, A. et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 10–32 (2023). - DOI - PubMed
    1. Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303–312 (2013). - DOI - PubMed
    1. Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909–1919 (2015). - DOI - PubMed
    1. Prager, G. W. et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N. Engl. J. Med. 388, 1657–1667 (2023). - DOI - PubMed
    1. Dasari, A. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402, 41–53 (2023). - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources